Login / Signup

A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.

Anna FurlanMichele CeaLaura PavanMonica GalliCristina ClissaSilvia MangiacavalliAnna Maria CafroStefania GirlandaFrancesca PatriarcaClaudia MinottoGiovanni BertolderoGregorio BarilàAnna PascarellaAlbana LicoRossella PaoliniNicholas RabassiNorbert PescostaMarika PorrazzoGiovanni De SabbataAlessandra PompaGiulia BegaStefania CavallinFrancesca GuidottiMagda MarcattiMaurizio RupoloAngelo BelottiFilippo GherlinzoniRenato Zambello
Published in: Cancer medicine (2024)
IRd might be effective and safe in RRMM pts with an indolent disease, in early lines of treatment, and who proved Len-sensitive, independent of age, and cytogenetic risk.
Keyphrases
  • multiple myeloma
  • hodgkin lymphoma
  • low dose
  • acute lymphoblastic leukemia
  • acute myeloid leukemia
  • cross sectional
  • diffuse large b cell lymphoma
  • combination therapy
  • newly diagnosed